Annovis Bio 

Yahoo Finance • 21 hours ago

Annovis launches $6 million registered direct offering

* Annovis Bio (NYSE:ANVS [https://seekingalpha.com/symbol/ANVS]) has entered into definitive agreements for the purchase of an aggregate of 4M shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.... Full story

Yahoo Finance • 22 hours ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer... Full story

Yahoo Finance • 2 days ago

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment

MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer... Full story

Yahoo Finance • 16 days ago

Annovis Appoints Mark Guerin as Chief Financial Officer

MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheime... Full story

Yahoo Finance • 25 days ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheime... Full story

Yahoo Finance • 2 months ago

Annovis Bio appoints CEO as acting CFO following executive resignation

Annovis Bio, Inc. (NYSE:ANVS) announced the upcoming resignation of Andrew Walsh, Vice President of Finance and Principal Financial Officer, effective August 22. According to a company statement based on a filing with the Securities and Ex... Full story

Yahoo Finance • 2 months ago

Annovis Bio (NYSE:ANVS) Reports Narrower Q2 2025 Loss, Advances Alzheimer's and Parkinson's Trials

Annovis Bio Inc. (NYSE:ANVS [https://www.chartmill.com/stock/quote/ANVS]) reported its second-quarter 2025 financial results, posting a net loss per share of $0.32, which was narrower than the analyst consensus estimate of a $0.41 loss. Th... Full story

Yahoo Finance • 4 months ago

Annovis Bio receives NYSE approval for compliance plan

* Annovis Bio (NYSE:ANVS [https://seekingalpha.com/symbol/ANVS]) received NYSE acceptance of its compliance plan regarding minimum market capitalization and stockholders' equity. * The company has 18 months from March 26, 2025, to rega... Full story

Yahoo Finance • 4 months ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the Company), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s... Full story

Yahoo Finance • 4 months ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD... Full story

Yahoo Finance • 5 months ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's... Full story

Yahoo Finance • 6 months ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheime... Full story

Yahoo Finance • 7 months ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) a... Full story

Yahoo Finance • 7 months ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer... Full story

Yahoo Finance • 8 months ago

Annovis to Host Patients’ Live Forum on February 27, 2025

MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS)  ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s... Full story

Yahoo Finance • 8 months ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as... Full story

Yahoo Finance • 8 months ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as... Full story

Yahoo Finance • 8 months ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as... Full story

Yahoo Finance • 8 months ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as... Full story

Yahoo Finance • 8 months ago

Annovis Bio, Inc. Announces Proposed Public Offering

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as... Full story